Access to hematopoietic stem cell transplant for patients with sickle cell anemia.
Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with phenotypically severe sickle cell anemia, and survival rates following matched-sibling HSCT are very high. However, despite cure rates much higher than HSCT for malignant diseases, the field has been slow to adopt this treatment modality for sickle cell anemia. This article explores some of the social forces that may contribute to this dichotomy.
['Meier|Emily Riehm|ER|', 'Johnson|Theodore|T|', 'Pinkney|Kerice|K|', 'Velez|Maria C|MC|', 'Kamani|Naynesh|N|', 'Odame|Isaac|I|']
D001741:African Americans D000755:Anemia, Sickle Cell D001290:Attitude D018864:Cultural Diversity D005260:Female D006297:Health Services Accessibility D054625:Healthcare Disparities D018380:Hematopoietic Stem Cell Transplantation D006630:Hispanic or Latino D006801:Humans D008297:Male D016134:Organizational Policy D011287:Prejudice D012577:Schools, Medical D064890:Social Determinants of Health D013337:Students, Medical
hematopoietic stem cell transplant sickle cell anemia diversity healthcare disparities hydroxyurea